Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Providing a PLATFORM: first results for liso-cel plus durvalumab in R/R B-cell NHL

Tanya Siddiqi • 19 Jul 2019
ICML 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T Checkpoint inhibitors Durvalumab Lisocabtagene maraleucel
PLATFORM

Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses the first results of the PLATFORM trial (NCT03310619). She discusses the safety of lisocabtagene maraleucel given with durvalumab to patients with relapsed/refractory aggressive B-cell non-Hodgkin lympoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Tanya Siddiqi

0:59
The potential of combination therapies to improve CAR-T outcomes in patients with CLL
Tanya Siddiqi • 10 Dec 2023
0:54
A research update in Richter's transformation from ASH 2023
Tanya Siddiqi • 10 Dec 2023
3:12
Liso-cel in R/R CLL: 24-month follow-up of TRANSCEND-CLL-004
Tanya Siddiqi • 10 Dec 2023
Novel therapies in NHL: BTK inhibitors & degraders
Nirav Niranjan Shah et al. • 17 Oct 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals